Shenzhen Kangtai Biological Products Management
Management criteria checks 2/4
Shenzhen Kangtai Biological Products' CEO is Xiang Miao, appointed in Dec 2021, has a tenure of 3.08 years. directly owns 0.17% of the company’s shares, worth CN¥27.55M. The average tenure of the management team and the board of directors is 3.1 years and 12.3 years respectively.
Key information
Xiang Miao
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.1yrs |
| Board average tenure | 12.3yrs |
Recent management updates
Recent updates
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%
Oct 13
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts
Sep 02Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up
Aug 13Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly
May 25Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations
May 03Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%
May 01Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion
Feb 27CEO
Xiang Miao (51 yo)
3.1yrs
Tenure
CN¥3,337,100
Compensation
Mr. Xiang Miao has been President at Shenzhen Kangtai Biological Products Co., Ltd. since December 29, 2021 and serves as its Director and served as its Vice President and Secretary.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 3.1yrs | CN¥1.37m | 0.012% CN¥ 2.0m | |
| President & Non-Independent Director | 3.1yrs | CN¥3.34m | 0.17% CN¥ 27.6m | |
| VP & Non-Independent Director | 3.1yrs | CN¥3.40m | 0.16% CN¥ 26.1m | |
| Board Secretary | 3.1yrs | CN¥955.50k | 0.014% CN¥ 2.2m |
3.1yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 300601's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Non-Independent Director | no data | CN¥3.34m | 0.17% CN¥ 27.6m | |
| VP & Non-Independent Director | 16.3yrs | CN¥3.40m | 0.16% CN¥ 26.1m | |
| Chairman of the Board | 16.3yrs | CN¥3.51m | 25.5% CN¥ 4.2b | |
| Chairman of the Supervisory Board | 12.3yrs | no data | 0.038% CN¥ 6.2m | |
| Independent Director | 3.1yrs | CN¥112.50k | no data | |
| Vice Chairman | 3.1yrs | CN¥2.11m | 0.0081% CN¥ 1.3m |
12.3yrs
Average Tenure
57yo
Average Age
Experienced Board: 300601's board of directors are seasoned and experienced ( 12.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 18:55 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Kangtai Biological Products Co., Ltd. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Diandian Li | China Merchants Securities Co. Ltd. |
| Bing Zhao | China Renaissance Securities |